Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
17.95 USD | -0.72% | -1.21% | +27.21% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With an expected P/E ratio at 50.65 and 42.15 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+27.21% | 1.07TCr | - | ||
-1.86% | 19TCr | C+ | ||
+0.56% | 11TCr | C | ||
-2.37% | 6.95TCr | A | ||
+13.40% | 4.64TCr | B- | ||
-7.31% | 4.6TCr | B- | ||
+7.97% | 4.25TCr | B+ | ||
+18.32% | 3.07TCr | B | ||
+17.70% | 2.56TCr | A- | ||
-7.51% | 2.33TCr | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- FPH Stock
- FSPKF Stock
- Ratings Fisher & Paykel Healthcare Corporation Limited